Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca's Oncology Success: Fueling Future Growth
12:54pm, Tuesday, 25'th Jun 2024
AstraZeneca is becoming a leader in the cancer therapeutics market, which is reflected in the growth of its share price. On June 25, 2024, Tagrisso, in combination with chemotherapy, was approved in J
AstraZeneca still a buy for one broker despite mixed Imfinzi data
11:00am, Tuesday, 25'th Jun 2024
AstraZeneca PLC (LSE:AZN) has put out mixed data for the Phase III trials of its immuno-oncology (IO) drug Imfinzi, notes broker ShoreCap. There was a positive result from the Phase III NIAGARA trial
AstraZeneca disappointed with failure of immunotherapy in early-stage lung cancer
02:57am, Tuesday, 25'th Jun 2024
AstraZeneca PLC (LSE:AZN) shared some disappointing news on an advanced lung cancer trial of its Imfinzi immunotherapy. Phase III trials showed the drug did not achieve statistical significance for it
BenevolentAI says second target identified by AstraZeneca collaboration
02:42am, Tuesday, 25'th Jun 2024
BenevolentAI (OTC:BAIVF) said that AstraZeneca PLC (LSE:AZN) has identified a target for systemic lupus erythematosus (SLE) using the former's artificial intelligence-driven drug discovery platform
AstraZeneca says Imfinzi fails in late-stage trial to treat type of lung cancer
02:25am, Tuesday, 25'th Jun 2024
AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.
3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains
04:30pm, Monday, 24'th Jun 2024
There are multiple reasons to consider exposure to pharmaceutical stocks for the long-term portfolio. First, pharma stocks have a low-beta and provide and help in reducing the overall beta of a portfo
3 No-Brainer Stocks to Buy for Under $100 Right Now
07:15am, Saturday, 22'nd Jun 2024
AstraZeneca should have lots of growth ahead. Bristol Myers Squibb has what it takes to navigate a major patent cliff.
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
11:11am, Thursday, 20'th Jun 2024
The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
12:01pm, Tuesday, 18'th Jun 2024
AstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoint
AstraZeneca's breast cancer drug combination fails in late-stage trial
03:06am, Tuesday, 18'th Jun 2024
AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patient
Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why
07:20pm, Monday, 17'th Jun 2024
In the most recent trading session, Astrazeneca (AZN) closed at $79.31, indicating a -0.35% shift from the previous trading day.
AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use
12:30pm, Monday, 17'th Jun 2024
The FDA approves AstraZeneca's (AZN) Imfinzi in combination with chemotherapy for treating mismatch repair deficient advanced/recurrent endometrial cancer based on data from the phase III DUO-E study.
3 Best Stocks to Buy From the Fantastic 5
06:00am, Monday, 17'th Jun 2024
Wall Street loves coming up with cute little phrases, whether that be “FANG” or the more recent Magnificent 7. However, Thornburg portfolio manager Nicholas Anderson would like investors to be fam
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
02:51am, Monday, 17'th Jun 2024
AstraZeneca said its blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer tha
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
11:18am, Thursday, 13'th Jun 2024
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.
